Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?

[1]  Alan W. Stitt,et al.  Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. , 2000, Kidney international.

[2]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. F. Weiss,et al.  Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.

[4]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in renal development and disease. , 2000, Journal of the American Society of Nephrology : JASN.

[5]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[6]  N. Ankrah,et al.  Toxicity of low levels of methylglyoxal: depletion of blood glutathione and adverse effect on glucose tolerance in mice. , 1999, Toxicology letters.

[7]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[8]  S. Lee-Huang,et al.  Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[10]  P. Jungers,et al.  Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. , 1998, Journal of immunology.

[11]  J. Baynes,et al.  Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: evidence for increased oxidative stress in uremia , 1998, FEBS letters.

[12]  Paul J Thornalley,et al.  Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. , 1998, The Journal of clinical investigation.

[13]  D. de Zeeuw,et al.  Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. , 1997, Kidney international.

[14]  H. Vlassara,et al.  Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. , 1997, Journal of immunological methods.

[15]  H. Vlassara,et al.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. , 1997, The Journal of clinical investigation.

[16]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[17]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[18]  G. Striker,et al.  Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[19]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[20]  R. Bucala,et al.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[22]  G. Striker,et al.  Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis. , 1995, Kidney international. Supplement.

[23]  A. Gugliucci,et al.  Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[24]  Paul J Thornalley,et al.  Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. , 1994, The Journal of biological chemistry.

[25]  J. Baynes.  AGEing growth factors: a role in diabetic vascular disease? , 1994, The Journal of clinical investigation.

[26]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[27]  R. Bucala,et al.  Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease , 1994 .

[28]  K. Takada,et al.  Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo , 1994, Infection and immunity.

[29]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[30]  G. Striker,et al.  Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I. , 1993, Endocrinology.

[31]  D. de Zeeuw,et al.  Quantification of renal low-molecular-weight protein handling in the intact rat. , 1993, Kidney international.

[32]  G. Striker,et al.  Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[34]  Z. Makita,et al.  Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.

[35]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[36]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[37]  A. Cerami,et al.  Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors , 1986, The Journal of experimental medicine.

[38]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[39]  Alan W. Stitt.  Vascular Complications of Diabetes , 1998 .

[40]  P. Hof,et al.  Receptors for Advanced Glycosylation Endproducts in Human Brain: Role in Brain Homeostasis , 1998, Molecular medicine.

[41]  G. Sava.  Pharmacological aspects and therapeutic applications of lysozymes. , 1996, EXS.

[42]  G. Striker,et al.  Studies by competitive PCR of glomerulosclerosis in growth hormone transgenic mice. , 1993, Kidney international. Supplement.